- 38 min ago Daily Horoscope 11 December 2019
- 9 hrs ago This Viral Video Of Chimpanzee Carefully Washing A T-Shirt Will Leave You Surprised
- 9 hrs ago Man Eats 'Banana Art' Worth USD 120,000, Says He Isn't Sorry!
- 11 hrs ago This Company Will Allow Their LGBTQ+ Employees To Avail HR Benefits On Declaring Their Partner
- Technology Amazon Headsets Fest Offers You Can Get On Headphones, Earphones, Truly Wireless Earbuds And More
- Sports Salzburg 0-2 Liverpool: Keita and Salah see Reds through in thrilling clash
- Movies Shahid Kapoor To Commence Shoot Of ‘Jersey’ On December 13 Despite Being Severely Ill
- News Senior Shiv Sena leader hints at patch-up with BJP, says 'Uddhav will take decision at right time'
- Finance Yes Bank Defers Decision On Allotment Of Shares To Citax; Braich's Bid Under Discussion
- Travel 7 Beautiful Churches in India For The Perfect Christmas Holiday
- Automobiles Orxa Mantis Electric Performance Motorcycle Revealed At India Bike Week 2019
- Education TOEFL Go! Global: A Mobile App From ETS To Stand Out In Exam
Alzheimer's disease is an irreversible, progressive brain disorder that causes the brain cells to degenerate and die, resulting in a decline in thinking, memory, behavioural and social skills.
According to the Alzheimer's Association, more than 4 million people in India have some form of dementia. It is estimated that at least 44 million people are living with dementia.
New treatments are still under way to stop, slow or prevent Alzheimer's disease and some of them have been unsuccessful.
The brain disorder is caused by the accumulation of plaque deposits in the brain, which eventually becomes toxic to brain cells. These plaque deposits are one of the biggest problems that are coming in the way to finding a cure for Alzheimer's disease because it's impossible to clear out the deposits from the brain tissue.
However, in a very recent breakthrough for Alzheimer's disease, United Neuroscience, a biotech company founded by Dr Chang Yi Wang, a prolific bio-inventor, her daughter Mei Mei Hu, and son-in-law, Louis Reese announced the results of Phase II a clinical trial on UB-311, an Alzheimer's vaccine.
This vaccine contains synthetic versions of amino acid chains that stimulate the antibodies to attack Alzheimer's protein in the blood, without causing any side effects. The antibodies were analysed in some patients and there was an almost 100% response rate.
Researchers believe that the vaccine can delay the onset of Alzheimer's disease by five years.
Currently, the company is working on the next clinical trial of the vaccine and its goal is to create innumerable vaccines that will be used to protect people from chronic illnesses.